The Frankenstein Eye Institute in Haifa, Israel, recently announced that for the first time, a scientific research team implanted an artificial cornea grown entirely from 3D printing of human corneal cells into the eye of a legally blind patient, and successfully restored his vision. It is regarded as a major breakthrough in the field of human tissue replication.
The operation was completed at the end of October. Rambam's team collaborated with Precise Bio, a company specializing in regenerative medicine and biomanufacturing tissue. The cornea used was not the traditional cornea donated by the deceased, but was "grown" by cultured human corneal living cells in the laboratory through 3D printing technology, and then used for transplantation. This innovative path means that the shortage of corneal donors is expected to be alleviated through laboratory-scale production in the future.
Corneal damage is one of the important causes of blindness worldwide and can be caused by trauma, infection or genetic diseases. Many patients can only rely on corneal transplantation to regain vision. In some developed countries, cornea donation tissue is relatively abundant, and patients usually only need to wait a few days to receive a transplant; but in countries lacking eye banks and centralized management systems, patients may have to wait for years, or even never wait for a suitable cornea. Therefore, once laboratories can mass-produce high-quality corneas, it will bring new hope to the millions of people at risk of corneal blindness.
The key to this technology is the "amplification effect": the research team obtained cells from the cornea donated by a healthy deceased, expanded and cultured it in the laboratory, and then prepared the corneal implant through a 3D bioprinting process. The report pointed out that with only one donated cornea, the laboratory successfully prepared about 300 corneal grafts that can be used for transplantation, greatly improving the utilization efficiency of a single donated tissue and providing a realistic path to alleviate the global shortage of corneal donors.
3D printed corneas are not a new concept that emerged overnight. As early as 2018, a team from Newcastle University in the UK reported research progress on 3D printing human corneas, and Precise Bio has continued to work with clinical experts over the past decade to gradually improve its bioprinting system and promote its transformation into clinical applications. This case clearly demonstrates that cutting-edge regenerative medicine technologies often need to go through years or even more than ten years of verification and regulatory processes from "proof of concept" in the laboratory to actually serving patients in the operating room.
What is more promising is that relevant companies said that their 3D bioprinting platform is not only suitable for cornea, but may also be expanded to print heart tissue and liver, kidney and other organ-related cell structures, which is expected to help solve the long-term serious imbalance between supply and demand in the field of organ transplantation in the future. However, such applications still require extensive clinical trials and regulatory review, and it will take some time before large-scale commercialization. However, for the patient group suffering from organ shortages, this successful implantation case undoubtedly sends a positive signal.